By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PDS Biotechnology Corporation 



Indianapolis  Indiana    U.S.A.
Phone: 513-475-6610 Fax: 513-221-1891


SEARCH JOBS








Company News
BIO2016: PDS Biotechnology Corporation CEO Frank Bedu-Addo Presenting At BIO 2016 6/7/2016 11:45:58 AM
PDS Biotechnology Corporation Reports Positive Phase 1 Study Results For PDS0101 Immunotherapy For HPV-Related Cancers 4/13/2016 5:59:42 AM
PDS Biotechnology Corporation Signs Agreement With NCI To Form Phase II Clinical Collaboration For Novel Cancer Immunotherapies Based On PDS' Versamune Platform Technology 2/9/2016 5:56:41 AM
Immunotherapy Company PDS Biotechnology Corporation Strengthens Senior Management Team, Adds Two Drug Development Executives 1/20/2016 6:28:08 AM
PDS Biotechnology Corporation Reports Positive Phase I Clinical Trial Results In Proprietary HPV-Cancer Immunotherapy 5/28/2015 6:14:23 AM
PDS Biotechnology Corporation Announces Appointment Of Biotech Industry Leader Sir Richard Sykes To Its Board Of Directors As Executive Chairman 12/18/2014 9:17:16 AM
NetScientific Invests In Next Generation, Immunotherapeutics Company, PDS Biotechnology Corporation 12/15/2014 8:53:15 AM
PDS Biotechnology Corporation Announces Treatment Of First Patient With PDS0101 Based On The Novel Versamune™ Cancer Immunotherapy Platform In A Phase 1 Clinical Trial 2/11/2014 10:02:51 AM
PDS Biotechnology Corporation Signs Worldwide Licensing Agreement With Merck KGaA (MKGAF.PK) for Versamuneā„¢ 7/9/2012 7:35:43 AM
PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract 3/2/2010 8:53:57 AM
12
//-->